Covered recipient · General Payments record
ELIZABETH N PARKER
Physician Assistants & Advanced Practice Nursing Providers Physician Assistant
General Payments · PY2021–2024
$3,375.67
- Reported across 38 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,623.22 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GlaxoSmithKline, LLC. | $364.98 | 3 |
| Medtronic, Inc. | $275.96 | 3 |
| Acerta Pharma LLC | $126.66 | 1 |
| Novo Nordisk AS | $124.98 | 1 |
| Mylan Specialty L.P. | $124.98 | 1 |
| Abbott Laboratories | $122.10 | 1 |
| Genentech USA, Inc. | $121.83 | 1 |
| Smith & Nephew, Inc. | $108.32 | 1 |
| Gilead Sciences, Inc. | $102.16 | 1 |
| Axsome Therapeutics, Inc. | $69.22 | 1 |
| ABBVIE INC. | $47.03 | 1 |
| Merck Sharp & Dohme Corporation | $35.00 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $122.10 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125299999 | CMS |
| ABBVIE INC. | $47.03 | 04/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107789494 | CMS |
| AstraZeneca Pharmaceuticals LP | $126.66 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105449943 | CMS |
| Axsome Therapeutics, Inc. | $69.22 | 05/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148356918 | CMS |
| Genentech USA, Inc. | $121.83 | 05/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133156703 | CMS |
| Gilead Sciences, Inc. | $102.16 | 04/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133717391 | CMS |
| GlaxoSmithKline, LLC. | $121.32 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115938013 | CMS |
| GlaxoSmithKline, LLC. | $121.83 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116667039 | CMS |
| GlaxoSmithKline, LLC. | $121.83 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116565060 | CMS |
| Medtronic, Inc. | $64.55 | 03/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116998408 | CMS |
| Medtronic, Inc. | $85.20 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116998410 | CMS |
| Medtronic, Inc. | $126.21 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116998412 | CMS |
| Merck Sharp & Dohme LLC | $35.00 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141589140 | CMS |
| Mylan Specialty L.P. | $124.98 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147285460 | CMS |
| Novo Nordisk Inc | $124.98 | 09/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100286708 | CMS |
| Smith+Nephew, Inc. | $108.32 | 03/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1149609707 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.